Drug data last refreshed 3h ago · AI intelligence enriched 5d ago
IBU is an oral suspension small-molecule NDA approved in 1989 by Abbott. The specific indication and mechanism of action are not documented in available data. This product is in the mature/declining phase of its lifecycle with loss of exclusivity approaching.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a defensive/optimization-focused commercial team rather than growth mode.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and Forehead
Magnetic Ressonance Imaging of Temporomandibular Joint
Establish Whether Hyperangulated Videolaryngoscopy (HAVL) Can be Used to Facilitate Tracheal Intubation Effectively and Safely in Unselected Adult Patients; Describe the Population in Whom HAVL Fails to Facilitate Tracheal Intubation Successfully, Identifying Any Contributory Characteristics.
Effects of Vagus Nerve Stimulation on Temporomandibular Disorders.
Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy Volunteers
Worked on IBU at Abbott? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Abbott is hiring 10 roles related to this product
Zero linked job openings indicate this is a mature, staffed product with limited hiring. Roles available focus on defending market share and managing the transition to generic competition rather than growth initiatives.